Thermo Fisher Scientific Adds Digital PCR to Genetic Analysis Capabilities
September 20, 2021 at 08:00 am EDT
Share
Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes. The QuantStudio Absolute Q provides an industry-best dPCR platform accelerating innovation in cancer research and more. dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays. The dPCR technology that powers the QuantStudio Absolute Q solution is already in use by biotech companies and academic institutions for longitudinal monitoring of cancer-driving mutations in liquid biopsy, precise quantification of gene inserts for cell therapy development, and copy number variation studies for earlier identification of genetic conditions in newborns.
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows:
- laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.;
- diagnostics equipment and products (15.3%);
- scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc.
Net sales break down by source of income into products sales (78.5%) and services (21.5%).
Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).